BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Special Drug Use Investigation of Glucobay OD

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Glucobay ODT (Acarbose, BAYG5421)

First Posted Date: 2012-09-14

Last Posted Date: 2014-10-20

Lead Sponsor: Bayer

Target Recruit Count: 2289

Registration Number: NCT01685502

Oral Rivaroxaban in Children With Venous Thrombosis

Phase 2

Completed

Conditions: Venous Thrombosis

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Active comparator
Drug: Rivaroxaban (BAY59-7939) suspension

First Posted Date: 2012-09-13

Last Posted Date: 2017-09-21

Lead Sponsor: Bayer

Target Recruit Count: 64

Registration Number: NCT01684423

Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD)

Phase 1

Completed

Conditions: Kidney Diseases

Interventions: Drug: Molidustat (BAY85-3934)
Drug: Placebo

First Posted Date: 2012-09-06

Last Posted Date: 2016-05-02

Lead Sponsor: Bayer

Target Recruit Count: 49

Registration Number: NCT01679587

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Phase 3

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Vitamin K antagonist (VKA)

First Posted Date: 2012-08-29

Last Posted Date: 2015-04-30

Lead Sponsor: Bayer

Target Recruit Count: 1504

Registration Number: NCT01674647

Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance

Completed

Conditions: Infection

Interventions: Drug: Ciprofloxacin (BAYQ3939)

First Posted Date: 2012-08-22

Last Posted Date: 2012-08-28

Lead Sponsor: Bayer

Target Recruit Count: 3274

Registration Number: NCT01670435

Pharmacy Based Pharmacoepidemiological Observational Study With Aspirin Protect 100 mg

Completed

Conditions: Effects, Longterm
Aspirin
Drug Safety

Interventions: Drug: Acetylsalicylic acid (Aspirin, BAYE4465)

First Posted Date: 2012-08-21

Last Posted Date: 2023-09-07

Lead Sponsor: Bayer

Target Recruit Count: 4235

Registration Number: NCT01669824

Compare Pharmacokinetic (PK) Profiles of Naproxen Sodium, Diphenhydramine Hydrochloride, and Naproxen Sodium and Diphenhydramine Hydrochloride Combination

Phase 1

Completed

Conditions: Therapeutic Equivalence

Interventions: Drug: Naproxen Sodium (Aleve, BAYH6689)
Drug: BAY98-7111
Drug: Diphenhydramine HCl

First Posted Date: 2012-08-16

Last Posted Date: 2014-08-21

Lead Sponsor: Bayer

Target Recruit Count: 32

Registration Number: NCT01666678

ESS505 Pre-hysterectomy Protocol

Not Applicable

Completed

Conditions: Contraception

Interventions: Device: ESS505 (Essure, BAY1454033)
Device: ESS505-A (Essure, BAY1454033)
Device: ESS305 (Essure, BAY1454032)

First Posted Date: 2012-08-14

Last Posted Date: 2016-08-04

Lead Sponsor: Bayer

Target Recruit Count: 66

Registration Number: NCT01664052

Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging

Phase 3

Completed

Conditions: Magnetic Resonance Imaging

Interventions: Drug: Gadobutrol (Gadovist, BAY86-4875)

First Posted Date: 2012-08-09

Last Posted Date: 2014-10-01

Lead Sponsor: Bayer

Target Recruit Count: 223

Registration Number: NCT01660841

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Phase 2

Completed

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Copanlisib (Aliqopa, BAY80-6946)

First Posted Date: 2012-08-08

Last Posted Date: 2024-07-17

Lead Sponsor: Bayer

Target Recruit Count: 227

Registration Number: NCT01660451

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy